Income Statement
TVARDI THERAPEUTICS, INC.
TVRD
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
- | 7.14 | 20.97 | 41.87 | 23.03 | 135.08 | 33.18 | 13.47 | 0.91 | 0.09 | 3.80 | 3.18 |
|
Cost of Revenue
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Gross Profit
|
- | 7.14 | 20.97 | 41.87 | 23.03 | 135.08 | 33.18 | 13.47 | 0.91 | 0.09 | 3.80 | 3.18 |
|
Operating Expenses
|
26.75 | 65.52 | 142.46 | 129.40 | 112.11 | 129.70 | 131.57 | 90.85 | 60.40 | 58.49 | 28.99 | 21.25 |
|
Research & Development
|
18.01 | 32.81 | 108.51 | 91.88 | 82.70 | 107.85 | 113.82 | 75.53 | 48.52 | 49.25 | 21.22 | 15.07 |
|
Selling, General & Administrative
|
8.74 | 26.53 | 27.78 | 30.26 | 29.41 | 21.85 | 17.75 | 15.32 | 11.87 | 9.23 | 7.77 | 6.18 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Operating Income
|
-26.75 | -58.38 | -121.50 | -87.54 | -89.08 | 5.39 | -98.38 | -77.38 | -59.49 | -58.40 | -25.19 | -18.07 |
|
Non-Operating Income
|
- | 12.88 | - | -2.06 | -0.64 | -2.33 | 8.81 | -2.98 | -1.16 | -0.65 | -0.10 | -0.13 |
|
Interest Income
|
0.70 | - | - | - | - | - | - | - | - | - | - | - |
|
Interest Expense
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Other Non-Op Income / Expense
|
7.16 | 2.83 | 3.59 | 2.06 | 0.64 | 2.33 | 4.49 | 2.98 | 1.16 | 0.65 | 0.10 | - |
|
Income Before Tax
|
- | -71.27 | - | -85.47 | -88.44 | 7.72 | -107.19 | -74.40 | -58.33 | -57.75 | -25.09 | -17.95 |
|
Income Tax Expense
|
- | -0.40 | - | 0.00 | 0.00 | -0.69 | -0.82 | -0.39 | -0.20 | -0.47 | -0.40 | -0.20 |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
Net Income
|
-18.21 | -70.87 | -118.51 | -85.47 | -88.44 | 8.41 | -106.37 | -74.01 | -58.13 | -57.28 | -24.69 | -17.75 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
-26.65 | -58.19 | -121.24 | -87.29 | -88.84 | 5.59 | -98.19 | -77.01 | -58.99 | -56.94 | -24.35 | -17.29 |
|
Earnings Per Share (Basic)
|
-2.46 | -15.53 | -2.19 | -1.59 | -1.74 | 0.18 | - | - | - | - | - | - |
|
Diluted EPS
|
-3.26 | -15.53 | -2.19 | -1.59 | -1.74 | 0.18 | - | - | - | - | - | - |
|
Weighted Average Shares
|
7.42 | 4.56 | 54.15 | 53.65 | 50.72 | 47.41 | 42.67 | 35.89 | 31.20 | 27.28 | 24.62 | 20.97 |
|
Diluted Weighted Avg Shares
|
7.78 | 4.56 | 54.15 | 53.65 | 50.72 | 47.92 | 42.67 | 35.89 | 31.20 | 27.28 | 24.62 | 20.97 |
|
Comprehensive Income
|
-18.21 | -70.61 | -117.10 | -86.79 | -88.87 | 8.31 | -106.09 | -74.06 | -58.20 | -57.24 | -24.73 | - |